Adiponectin: is it a novel treatment modality to alleviate liver injury in non-alcoholic fatty liver disease (NAFLD)?
Aygun
Cem
C
Kocaman
Orhan
O
Senturk
Omer
O
D052242:Adiponectin / Q000627:therapeutic use*; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000293:injuries / Q000503:physiopathology; D051379:Mice; D008954:Models, Biological; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D052242:Adiponectin; D005227:Fatty Acids; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha